CellFlow - Chemical-Free Cell Isolation for Commercial-Scale Cell Therapy Manufacturing

CellFlow - 用于商业规模细胞治疗制造的无化学细胞分离

• 批准号: 104195
• 金额: $ 90万
• 依托单位: LABXERO LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2018
• 资助国家: 英国
• 起止时间: 2018 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=104195
• 关键词: CellFlow; Chemical; Free; Cell; Isolation

Cell-derived products have potential as promising therapeutic approaches for the treatment of a wide range of conditions (e.g. neurodegenerative disorders, cancer, cardiac failure). Cell therapies require large scale supplies of viable cells at high purity levels, driving advancements in cell separation technologies to address downstream processing bottlenecks to achieving high separation efficiency, throughput and sample purity at scale. The key project objectives are to develop, optimise and scale-up a low-cost, chemical-free continuous-flow cell separator/concentrator and demonstrate improved cell extraction efficiency and cell viability in pilot-scale cell therapy manufacturing trials. The proposed innovation lies in proprietary acoustic enhancements for particle manipulation, that provide a cost-effective, contactless, scalable solution for downstream bioprocessing - specifically cell/particle separation/concentration. Ultra low-cost, low energy acoustic methods enable increased throughput, resulting in a step-change beyond state-of-the-art downstream processing techniques. Successful project outcomes will overcome a key biomanufacturing bottleneck, helping to improve commercial viability of the UK Cell Therapy industry, thereby unlocking a sustainable UK bioeconomy.

细胞衍生产品具有作为治疗多种病症（例如神经退行性疾病、癌症、心力衰竭）的有前景的治疗方法的潜力。细胞疗法需要大规模供应高纯度水平的活细胞，从而推动细胞分离技术的进步，以解决下游加工瓶颈，从而实现大规模的高分离效率、通量和样品纯度。该项目的主要目标是开发，优化和扩大低成本，无化学品的连续流动细胞分离器/浓缩器，并在中试规模的细胞治疗生产试验中证明提高的细胞提取效率和细胞活力。提出的创新在于颗粒操作的专有声学增强，为下游生物处理提供了一种具有成本效益的、非接触式的、可扩展的解决方案-特别是细胞/颗粒分离/浓缩。超低成本、低能耗的声学方法能够提高产量，从而超越最先进的下游处理技术。成功的项目成果将克服关键的生物制造瓶颈，帮助提高英国细胞治疗行业的商业可行性，从而开启可持续的英国生物经济。